TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38948164

Group type: EXPERIMENTAL
Intervention: Visepegenatide
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 38948455

Group type: EXPERIMENTAL
Intervention: Bulk Density (BD) synthetic CT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tissue Stratification (TS) synthetic CT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Deep-Learning (DL) synthetic CT
Number of subjects: 36
Study: 38948487

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment plus exercise therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham acupuncture plus exercise therapy
Number of subjects: 80
Study: 38948837

Group type: EXPERIMENTAL
Intervention: MUC1 tumor antigen vaccine
Number of subjects: 68
Study: 38949541

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 2292

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 2292

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 2292

Group type: COMPARATOR
Intervention: Labetalol vs Standard Care
Number of subjects: 2292

Group type: COMPARATOR
Intervention: Nifedipine vs Standard Care
Number of subjects: 2292

Group type: EXPERIMENTAL
Intervention: Labetalol vs Nifedipine
Number of subjects: 2292

Group type: EXPERIMENTAL
Intervention: Labetalol and Nifedipine
Number of subjects: 2292
Study: 38949715

Group type: EXPERIMENTAL
Intervention: Complete decongestive therapy (CDT) 5 days a week for 3 weeks in MetS group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Complete decongestive therapy (CDT) 5 days a week for 3 weeks in control group
Number of subjects: 40
Study: 38949758

Group type: EXPERIMENTAL
Intervention: Vupanorsen 80 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vupanorsen 160 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study: 38949814

Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking (UCM)
Number of subjects: 971

Group type: COMPARATOR
Intervention: Early Cord Clamping (ECC)
Number of subjects: 971
Study: 38949813

Group type: EXPERIMENTAL
Intervention: Combined nudges (clinician peer comparisons + patient priming questionnaires)
Number of subjects: 4450

Group type: COMPARATOR
Intervention: Clinician nudge only (active control + weekly peer comparisons)
Number of subjects: 4450

Group type: COMPARATOR
Intervention: Patient nudge only (active control + preclinic electronic communication)
Number of subjects: 4450

Group type: COMPARATOR
Intervention: Active control (clinician text message reminders)
Number of subjects: 4450
Study: 38949862

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention with high immersion levels
Number of subjects: 252

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 252
Study: 38949906

Group type: EXPERIMENTAL
Intervention: 10 hr of SOP training (n = 70)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 20 hr of SOP training (n = 73)
Number of subjects: 216

Group type: COMPARATOR
Intervention: 10 hr of internet navigation control training (n = 73)
Number of subjects: 216
Study: 38950286

Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Number of subjects: 11
Study: 38950311

Group type: EXPERIMENTAL
Intervention: MR-proANP and NT-proBNP combined with clinical variables
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: MR-proANP and NT-proBNP
Number of subjects: 621
Study: 38950321

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (SCRT) followed by six cycles of consolidation immunochemotherapy with capecitabine and oxaliplatin and toripalimab (Group A)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Two cycles of induction immunochemotherapy followed by SCRT and the rest four doses (Group B)
Number of subjects: 121
Study: 38950376

Group type: EXPERIMENTAL
Intervention: Treatment based on voiding diaries (dDAVP for nocturnal polyuria with normal MVV; enuresis alarm for reduced MVV and no nocturnal polyuria)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Randomly allocated treatment (dDAVP or alarm)
Number of subjects: 324
Study: 38950397

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 196

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 196
Study: 38950423

Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Bacillota/Bacteroidota ratio
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Food consumption patterns
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Microbiota alterations
Number of subjects: 178
Study: 38950555

Group type: EXPERIMENTAL
Intervention: DLL3-targeted imaging tracer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DLL3 PET-CT imaging
Number of subjects: 18
Study: 38950668

Group type: EXPERIMENTAL
Intervention: Electronic physician notification with customized guideline recommendations for the management of severe aortic stenosis
Number of subjects: 940

Group type: COMPARATOR
Intervention: Usual care (no notification)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Electronic physician notification
Number of subjects: 940
Study: 38950689

Group type: EXPERIMENTAL
Intervention: V-Wave interatrial shunt device implantation at the time of MitraClip procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: MitraClip procedure
Number of subjects: 0
Study: 38950925

Group type: EXPERIMENTAL
Intervention: Niraparib first-line maintenance therapy
Number of subjects: 487
Study: 38950931

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (21 mL of 2% lidocaine and 50 μg fentanyl)
Number of subjects: 22
Study: 38950987

Group type: EXPERIMENTAL
Intervention: AI decision support software
Number of subjects: 228

Group type: COMPARATOR
Intervention: No AI decision support software (control group)
Number of subjects: 228
Study: 38950991

Group type: EXPERIMENTAL
Intervention: Full/near-full optical treatment requiring wear for at least half their waking hours for 24 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full/near-full optical treatment
Number of subjects: 0
Study: 38950995

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (BoNT-A) treatment at different timings
Number of subjects: 960

Group type: COMPARATOR
Intervention: Rehabilitation without BoNT-A treatment
Number of subjects: 960
Study: 38950994

Group type: EXPERIMENTAL
Intervention: Cerina (CBT-based mobile app) for 6 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-list control group (optional on-campus well-being services for 6 weeks)
Number of subjects: 90
Study: 38950993

Group type: EXPERIMENTAL
Intervention: Graded Exposure Therapy (GET)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Prescribed aerobic exercise
Number of subjects: 220

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 220
Study: 38950997

Group type: EXPERIMENTAL
Intervention: Standard inactivated quadrivalent influenza vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 38951007

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen by Nasal Cannula (HFNC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Oxygen Therapy
Number of subjects: 0
Study: 38951006

Group type: EXPERIMENTAL
Intervention: Strong Families programme (7-hour family skills group intervention over 3 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Strong Families programme
Number of subjects: 90
Study: 38951008

Group type: EXPERIMENTAL
Intervention: Interest in pregnancy following diagnosis
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Fertility preservation
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Pregnancy rates
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Psychosocial outcomes
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Tumour analyses
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis of indeterminate potential
Number of subjects: 1302
Study: 38951012

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBM) applied to bilateral knees and lumbar paraspinal points.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control (not explicitly detailed in the abstract).
Number of subjects: 0
Study: 38951253

Group type: EXPERIMENTAL
Intervention: Home-based computerized EF intervention for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Home-based computerized EF intervention including SC tasks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 38951256

Group type: EXPERIMENTAL
Intervention: ChatGPT
Number of subjects: 200
Study: 38951314

Group type: EXPERIMENTAL
Intervention: TG-LASIK
Number of subjects: 34

Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 34
Study: 38951507

Group type: EXPERIMENTAL
Intervention: AIMS
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: PAM50
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Different IBCMS methods
Number of subjects: 446
Study: 38951532

Group type: EXPERIMENTAL
Intervention: Mobile behavior change program for weight loss
Number of subjects: 0
Study: 38951699

Group type: EXPERIMENTAL
Intervention: Early integration of specialised palliative care (SPC) alongside tumour-specific palliative treatment
Number of subjects: 118

Group type: COMPARATOR
Intervention: Tumour-specific treatment alone (Control)
Number of subjects: 118
Study: 38951777

Group type: EXPERIMENTAL
Intervention: SM-ART intervention (six weekly sessions of 60 to 90 minutes)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 38951803

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Aerobic and resistance exercise
Number of subjects: 32
Study: 38951815

Group type: EXPERIMENTAL
Intervention: Health literacy measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up every 2 years via telephone call
Number of subjects: 0
Study: 38951853

Group type: EXPERIMENTAL
Intervention: Trastuzumab-emtansine (T-DM1)
Number of subjects: 37
Study: 38951902

Group type: EXPERIMENTAL
Intervention: CBD oral solution
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 38951929

Group type: EXPERIMENTAL
Intervention: RECOVERY trial participants
Number of subjects: 38510

Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 38510
Study: 38951940

Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic toric IOL Clareon CNW0T3-9
Number of subjects: 130
Study: 38952054

Group type: EXPERIMENTAL
Intervention: Acalabrutinib plus obinutuzumab
Number of subjects: 10
Study: 38952209

Group type: EXPERIMENTAL
Intervention: Benzodiazepine discontinuation programme
Number of subjects: 73
Study: 38952498

Group type: COMPARATOR
Intervention: Lumbar stability exercise (LSE) group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lumbar stability exercise with teeth clenching (LSETC) group
Number of subjects: 80
Study: 38952513

Group type: EXPERIMENTAL
Intervention: Informing patients with video about intensive care before cardiac surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no video information)
Number of subjects: 90
Study: 38952554

Group type: EXPERIMENTAL
Intervention: Regorafenib (oral, maximum daily dose of 160 mg for weeks 1-3 of each 4-week cycle)
Number of subjects: 143
Study: 38952672

Group type: EXPERIMENTAL
Intervention: Short-course oxaliplatin-based chemotherapy alternating with immune checkpoint blockade (ICB)
Number of subjects: 38
Study: 38952731

Group type: EXPERIMENTAL
Intervention: COVID-19 disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health services utilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative study
Number of subjects: 0
Study: 38952780

Group type: EXPERIMENTAL
Intervention: Dolutegravir-based ART
Number of subjects: 0
Study: 38952884

Group type: EXPERIMENTAL
Intervention: Betamethasone (2 doses of 12mg intramuscular)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 doses of 12mg intramuscular)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo (2 doses)
Number of subjects: 146
Study: 38953034

Group type: EXPERIMENTAL
Intervention: Icanbelimod 0.5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Icanbelimod (various doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 38953152

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (healthy participants)
Number of subjects: 7
Study: 38953334

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 40
Study: 38953542

Group type: EXPERIMENTAL
Intervention: Higher adalimumab induction dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard adalimumab dosing regimen
Number of subjects: 0
Study: 38953600

Group type: EXPERIMENTAL
Intervention: Higher adalimumab induction regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard adalimumab dosing regimen
Number of subjects: 0
Study: 38953850

Group type: EXPERIMENTAL
Intervention: N-803 (100, 200, or 400 μg) plus BCG (50 mg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: N-803 (400 μg) plus BCG (50 mg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: N-803 (400 μg) alone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: N-803 plus BCG
Number of subjects: 91
Study: 38953855

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil plus bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trifluridine/tipiracil alone
Number of subjects: 0
Study: 38953934

Group type: EXPERIMENTAL
Intervention: High FDG Ki group (n=8, Ki > 2.779 ml/min/100 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low FDG Ki group (n=7, Ki ≤ 2.779 ml/min/100 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Reduction in Ki > 73.1%
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High FDG Ki group after hypo-CCRT
Number of subjects: 15
Study: 38953936

Group type: EXPERIMENTAL
Intervention: Video-based cervical stabilization exercises, performed three times a week for six weeks in addition to routine medication.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group continued routine medication only.
Number of subjects: 26
Study: 38953938

Group type: EXPERIMENTAL
Intervention: Balloon-expandable stent (BES)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Self-expandable stent (SES)
Number of subjects: 201
Study: 38954010

Group type: EXPERIMENTAL
Intervention: SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1) (Arm A)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (Arm B)
Number of subjects: 13
Study: 38954035

Group type: EXPERIMENTAL
Intervention: Thrombectomy in the elderly prediction score (TERPS)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Clinical and radiological parameters used to calculate TERPS
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: TERPS risk prediction score
Number of subjects: 218
Study: 38954131

Group type: EXPERIMENTAL
Intervention: Transurethral catheterization (TUC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Suprapubic catheterization (SPC)
Number of subjects: 240
Study: 38954149

Group type: EXPERIMENTAL
Intervention: Family support intervention delivered by the interprofessional ICU team
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 38954176

Group type: EXPERIMENTAL
Intervention: Zolbetuximab
Number of subjects: 0
Study: 38954217

Group type: EXPERIMENTAL
Intervention: Closed-loop spinal cord stimulation (CL-SCS)
Number of subjects: 135
Study: 38954226

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg SC at baseline, weeks 1 and 2, and every 2 weeks thereafter until week 16
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg SC
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 38954317

Group type: EXPERIMENTAL
Intervention: TV-46000 once monthly (q1m)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: TV-46000 once every 2 months (q2m)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo (from RISE)
Number of subjects: 336
Study: 38954402

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 38954415

Group type: EXPERIMENTAL
Intervention: Usual care plus abstinence-contingent financial incentives (UC plus FI)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 320
Study: 38954433

Group type: EXPERIMENTAL
Intervention: UV4.me [basic]
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: UV4.me2 [enhanced]
Number of subjects: 1369

Group type: COMPARATOR
Intervention: e-pamphlet
Number of subjects: 1369
Study: 38954475

Group type: EXPERIMENTAL
Intervention: Acupuncture (30 sessions over 10 weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Biofeedback therapy (3 sessions over 10 weeks)
Number of subjects: 85
Study: 38954482

Group type: EXPERIMENTAL
Intervention: Supporting Self-Management of Healthy Behaviors intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38954674

Group type: EXPERIMENTAL
Intervention: Cardiac Brief Intervention (nurse-led, 20 minutes emotional and educational support discussion with a leaflet)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care information (Control group)
Number of subjects: 40
Study: 38954680

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (Myfembree®) after surgical myomectomy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard of care (SoC) after surgical myomectomy
Number of subjects: 136
Study: 38954692

Group type: EXPERIMENTAL
Intervention: aPDT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tongue scraper
Number of subjects: 52

Group type: COMPARATOR
Intervention: Probiotic capsule (Lactobacillus salivarius WB21, 6.7 x 108 CFU, xylitol 280mg, 3 times a day for 14 days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control appointments
Number of subjects: 52
Study: 38954699

Group type: EXPERIMENTAL
Intervention: Social cognition assessed with the NEPSY II test
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Emotional markers assessed with the Differential Emotion Scale IV and the Revised Beliefs About Voices Questionnaire
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Social cognition and emotional markers
Number of subjects: 40
Study: 38954701

Group type: EXPERIMENTAL
Intervention: Intervention arm with free first-line ACT for positive mRDT and PMRs receiving USD $0.2 for every mRDT performed
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control arm offering subsidized mRDT testing for USD $0.66
Number of subjects: 48
Study: 38954782

Group type: EXPERIMENTAL
Intervention: TK216 administered as a 14-day continuous infusion
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: TK216 plus vincristine (added on day 1 after cycle 2, per investigators' choice)
Number of subjects: 85
Study: 38954785

Group type: EXPERIMENTAL
Intervention: CaboNivo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CaboNivoIpi
Number of subjects: 120
Study: 38954834

Group type: EXPERIMENTAL
Intervention: Genetic deletion of JAM-C (Junctional Adhesion Molecule-C) in leukemic stem cells (LSCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AP-1/TNF-α gene signature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LSC-17 score
Number of subjects: 0
Study: 38954844

Group type: EXPERIMENTAL
Intervention: Serial prophylactic exchange blood transfusion (SPEBT); 12 patients received at least 1 SPEBT, 11 received ≥3.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard care (control); 16 control participants required at least 1 transfusion.
Number of subjects: 35
Study: 38954860

Group type: EXPERIMENTAL
Intervention: Galactomannan (GM) analysis in exhaled breath condensate (EBC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cytokine profiling (IL-6 and TNF-α)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bronchoalveolar lavage fluid (BALF) GM levels
Number of subjects: 75
Study: 38954874

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (NS)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Quetiapine extended release (XR)
Number of subjects: 676
Study: 38954899

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel, gemcitabine, and oxaliplatin (first-line treatment)
Number of subjects: 67
Study: 38954929

Group type: EXPERIMENTAL
Intervention: MI-Walk intervention (motivational enhancement therapy with 3 counseling sessions, Fitbit Charge 2, exercise diaries, telephone follow-up, motivational emails, optional walking groups)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (PA education alone)
Number of subjects: 60
Study: 38955178

Group type: EXPERIMENTAL
Intervention: Oral terameprocol at 1,200 mg/day (n=3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral terameprocol at 2,400 mg/day (n=6)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral terameprocol at 3,600 mg/day (n=3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral terameprocol at 6,000 mg/day (n=2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral terameprocol at 6,000 mg/day in fed state (n=4)
Number of subjects: 20
Study: 38955351

Group type: EXPERIMENTAL
Intervention: Maternal gut microbiota in 1st trimester with excessive GWG
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Gut microbiota trajectory across gestations
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Gut microbiota composition in relation to GWG
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Richness index of alpha diversity
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Evenness index in 2nd trimester
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Taxonomic differences in 1st trimester
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Taxonomic differences in 2nd and 3rd trimesters
Number of subjects: 110
Study: 38955352

Group type: EXPERIMENTAL
Intervention: Ligilactobacillus salivarius V4II-90 at 1 × 10^9 cfu/day for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 38955368

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 844

Group type: COMPARATOR
Intervention: Plasma solution
Number of subjects: 844